(e.g., Faecalibacterium prausnitzii), and increase of taxa with invasive potential (e.g., Enterobacteriaceae). 2, 3 Some of these alterations also characterize healthy carriers of IBD genetic risk factors, 4, 5 supporting that microbiota changes precede and could be causally involved in the development of intestinal inflammation. Further studies of genetic alterations that shape the intestinal microbiota may help define how these contribute to disease pathogenesis but are challenging given the added effects of environmental factors and the small effects of most common genetic risk variants. [6] [7] [8] Studying patients with monogenic disorders at risk of IBD, who by definition harbor mutations with high functional impact on a single gene, may help us to overcome this challenge.
We previously described the monogenic Familial GUCY2C diarrhea syndrome (FGDS) in a large Norwegian kindred, with more than 25% of the adult patients diagnosed with concomitant Crohn's disease (CD). 9 The causative mutation in GUCY2C increases the activity of guanylate cyclase C (GC-C). This is an epithelial enzyme-linked receptor that regulates intestinal hydration and pH by facilitating chloride and hydrogen carbonate efflux from the intestinal epithelium through the cystic fibrosis transmembrane conductance regulator and by inhibiting sodium reabsorption and hydrogen efflux through the sodium-hydrogen exchanger 3 (NHE3). 10 The impact of GC-C activation elicited by bacterial toxins on intestinal hydration has since long been identified as 1 of the major mechanisms for infectious diarrhea. 10 Accumulating evidence now also links altered signaling through this pathway to IBD and colorectal cancer, [11] [12] [13] [14] [15] [16] but mechanistic insights are limited and derive mainly from animal models. Studies of intestinal inflammation in Gucy2c knockout mice have reported inconsistent results, but the models do show impairment of the epithelial barrier, increased invasiveness of pathogenic bacteria, increased tumorigenesis, and alterations in the intestinal microbiota. [17] [18] [19] On the other hand, mice lacking the NHE3 protein display IBD-like alterations in the intestinal microbiota, and similar to patients with FGDS, increased intestinal hydration and liability to colonic and ileal inflammation. 20, 21 Importantly, when treated with antibiotics or reared in germ-free conditions, these mice show reduced intestinal inflammation. 21 Overall, these data suggest that IBD susceptibility may be mediated by alterations in the intestinal microbiota caused by changes in intestinal ion transportation regulated by GC-C.
Given the evidence that GC-C activity affects the intestinal environment and the susceptibility to intestinal inflammation, we hypothesized that GC-C activation also shapes the human intestinal microbiota. This was investigated by studying the fecal microbiota in patients with FGDS stratified for CD status, compared with panels of related and unrelated healthy controls (HCs) as well as unrelated disease controls with IBD.
METHODS Participants
Twenty-five adult patients from the same family diagnosed with FGDS at Haukeland University Hospital (Bergen, Norway) were invited to participate in this study, together with 23 healthy family controls (spouses or adult-related HC). Unrelated HC were randomly selected from the national Norwegian Bone Marrow Donor Registry (Oslo, Norway), and unrelated patients with IBD were recruited from the outpatient clinic at Oslo University Hospital Ullevål (Oslo, Norway). IBD diagnosis was based on findings at colonoscopy, histology, and accepted clinical criteria. 22 Harvey Bradshaw Index (HBI) for patients with CD and Simple Clinical Colitis Activity Index for patients with ulcerative colitis (UC) were estimated as measures of disease activity at enrollment using questionnaire and clinical data. 23, 24 The study was performed in accordance with the Declaration of Helsinki and approved by the Regional Committee for 25 Data were ultimately supplemented and controlled against hospital records for patients with FGDS and IBD.
For stool sampling, a standardized collection device was used by all participants after voiding. 26 Samples for microbiota analysis were transported using collection tubes with stool DNA stabilizer (Stratec Molecular GmbH, Berlin, Germany), 27 whereas samples for measurement of calprotectin were shipped in a dry sterile container (Sarstedt, Nümbrecht, Germany). All samples were frozen at minimum 2208C on arrival, and only samples with ,72 hours from collection to freezing were included, according to the recommendation of the manufacturer. Patients with FGDS and related HC provided 2 stool samples with an interval of at least 1 week. The one delivered first was selected for further analyses provided that it satisfied inclusion criteria and had sufficient sequencing quality. The second sample was then used to assess gut microbiota stability. We excluded all participants exposed to antibiotics during the preceding 4 weeks, together with participants with gastrointestinal stoma or participants reporting to be on specific diets (e.g., vegan, vegetarian, gluten-free, and milk-free diets).
DNA was extracted as previously described, using the PSP Spin Stool DNA Kit (Stratec Molecular GmbH), and stored at 2808C until further processing. 28 Fecal calprotectin was measured using Calpro Calprotectin ELISA (Calpro AS, Oslo, Norway) and was performed by the manufacturer.
Library Preparation and Sequencing
Library preparations were performed as previously described. 28, 29 In short, libraries were constructed from amplicons of the V3-V4 region of the 16S rRNA gene. Quality control was performed on a Bioanalyzer (Agilent Technologies, Santa Clara, CA) using the Agilent High Sensitive DNA Kit (Agilent Technologies). Sequencing was performed on the Illumina MiSeq platform, using the v3 kit, (Illumina, San Diego, CA), at the Norwegian Sequencing Centre (Oslo, Norway). An additional validation library from all the patients with FGDS and healthy relatives and a subset of the unrelated HCs (N ¼ 72) using amplicons of the V4 region was generated and sequenced at Broad Institute (Boston, MA) according to an established protocol. 30 Data from the sequencing of the V3-V4 amplicons are reported unless otherwise stated.
Sequence Processing and Data Quality Control
Paired-end reads were merged with FLASH version 1.2.11. 31 The merged reads were demultiplexed and quality controlled using default values in QIIME version 1.8.0 (Quantitative Insights Into Microbial Ecology) software package. 32 Operational taxonomic unit clustering and taxonomy classification were performed in QIIME using closed-reference operational taxonomic unit picking with uclust version 1.2.22q against the Greengenes database (version 13.8, preclustered at 97% sequence identity). 33, 34 Operational taxonomic units containing only 1 sequence were discarded, together with samples yielding ,8751 mapped reads.
Assessment of Food Habits in Patients with FGDS and Healthy Relatives
Patients with FGDS and related HCs completed a validated self-administered Norwegian food frequency questionnaire. 35 The contribution of each nutrient to total energy intake (EI) was calculated and denoted E%. 36 Basal metabolic rate (BMR) was calculated according to the Schofield equation. 37 EI/BMR ratio was also calculated, providing a measure of calorie intake normalized to resting energy requirement.
Statistical Analysis
For comparisons of continuous variables, Mann-Whitney U or T tests were used where appropriate. Comparisons of categorical variables were performed with chi-square test or Fisher's exact test as required. Depending on the data distribution, correlation analyses were performed either with Spearman's rank correlation test or Pearson's correlation test. False discovery rate (FDR) was calculated in R according to Benjamini-Hochberg, FDR-corrected P-values were denoted as "Q FDR ." Calculations of rarefied alpha diversity (Chao 1 bacterial richness estimate [chao 1]), the Shannon diversity index and Simpson diversity index were performed in QIIME. PER-MANOVA was used to compare beta diversity between study groups (unweighted Unifrac). The linear discriminant analysis effect-size tool (LEfSe, version 1.0) and Multivariate Association with Linear Models framework (MaAsLin, version 1.0.1) were accessed online from http://huttenhower.sph.harvard.edu/ galaxy/ (The Huttenhower Lab, Department of Biostatistics, Harvard School of Public Health, Boston, MA) using standard parameters. 38, 39 Unless otherwise specified, all other calculations were performed in SPSS (version 23, IBM, NY).
For screening of taxa differing between unrelated HC and FGDS, the significance threshold was set at Q FDR # 0.05. In MaAsLin analyses, IBD status, age, body mass index (BMI), and number of antibiotic courses last year were used as covariates. IBD status was used as subclass in LEfSe analyses comparing FGDS and HC. Findings were then evaluated by comparison of taxa abundances between FGDS without CD (to exclude CDrelated changes) and related HC using a significance threshold at P , 0.05.
RESULTS

Clinical Characterization
Twenty adult patients with FGDS (age 18-74 yr, 80% of the invited, 5 declined to participate), 11 related HC (age 33-72 yr, 48% of the invited, 11 declined to participate), 263 unrelated HC (age 30-61 yr), and 46 patients with IBD (age 22-69 yr) were included, as shown in Table 1 . Recruitment and exclusion of unrelated HC and IBD controls were previously described. 40 Patients with FGDS were leaner than unrelated HC as measured by BMI (P ¼ 0.03). This difference was driven by the subgroup (N ¼ 5) of patients with FGDS diagnosed with CD. The unrelated patients with IBD were younger (P ¼ 0.008) and had a lower BMI (P ¼ 0.007) than the unrelated HC. In FGDS with CD (N ¼ 5), disease activity according to HBI ranged from 5 to 8 (median 7), and in conventional patients with CD (N ¼ 9), HBI ranged from 8 to 11 (median 8) (see Table S1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B636). These values are close to the cutoff between mild and moderate disease activity in CD, which is usually set at HBI ¼ 7. Disease location did not differ between these 2 groups, but strictures and fistula were more common in conventional CD (P ¼ 0.03). Fecal calprotectin was significantly higher in the conventional patients with CD (median 361, P ¼ 0.01) but not in the patients with UC (median 153, P ¼ 0.074) compared with FGDS with CD (median 31) (see Tables S1 and S2 , Supplemental Digital Content 1, http://links.lww.com/IBD/B636). Four patients with FGDS (20%) previously underwent surgery of the small intestine for acute intestinal obstruction.
Microbial Composition Separates Patients with FGDS from Patients with HC and IBD
Fecal bacterial composition was clearly distinct between patients with FGDS, HC, and patients with IBD (P , 0.001, unweighted UniFrac), as shown in Figure 1 . Importantly, the gut microbiota of related HC was similar to that of unrelated HC (P ¼ 0.09). The intestinal microbiota also displayed a high degree of stability in FGDS and related HC when analyzing paired samples taken at least 1 week apart (see The difference between FGDS and HC was not attributed to differences in intraindividual (alpha) diversity, which was similar in FGDS and HC (Fig. 2) . By contrast, alpha diversity was significantly reduced in IBD compared with patients with FGDS (all metrics: P , 0.001) and with unrelated HC (P , 0.001, Fig. 2 ). There was a trend toward lower alpha diversity in FGDS patients with CD compared with those without CD (P ¼ 0.095, see 
Many Microbial Lineages Differ Between Patients with FGDS and HCs
In total, 112 taxa on all taxonomic levels differed between patients with FGDS and unrelated HC (Q FDR , 0.05, see Table S3 , Supplemental Digital Content 1, http://links.lww.com/IBD/B636). The phylogenetic relationships between taxa that separated unrelated HC and FGDS with consistency (regardless of CD status) according to linear discriminant analysis effect size are depicted in Figure 3 . Further validation of findings using multivariate analysis (MaAsLin) and comparison against healthy family members (¼related HC) reduced the number of significant taxa to 28 (Table 2) .
Patients with FGDS displayed a marked enrichment of Enterobacteriaceae, (phylum Proteobacteria, Figs. 3 and 4A) and an almost complete disappearance of Bifidobacterium (phylum Actinobacteria, Figs. 3 and 4B), compared with HC. The quantitatively largest changes were found within the Firmicutes phylum, including a major decrease in the Faecalibacterium genus in patients with FGDS (Figs. 3  and 4C ). More than 99% of the Faecalibacterium sequences were annotated to the species F. prausnitzii. All reported associations were also observed when comparing FGDS with related HC.
The archaea genus Methanobrevibacter showed a marked enrichment in patients with FGDS compared with unrelated HC and IBD, despite an overall low abundance in the V3-V4 data set (see Table S1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B636). Archaea are sensitive to the choice of marker when analyzing the hypervariable 16S rRNA gene. 41 We, therefore, investigated a subset of the samples sequenced for validation purposes (all patients with FGDS and related HCs and 66 (25%) of the unrelated HCs) using V4-specific primers. The enrichment of Methanobrevibacter in patients with FGDS observed in the V3-V4 data was confirmed, both when comparing FGDS with related HC (P ¼ 0.032) and unrelated HC (P , 0.001, Table 2 ). There was a 10-fold increase in the relative abundance of the archaeal phylum Euryarchaeota in the V4 data set compared with the same subset of the original V3-V4 data set, but with a strong correlation between the data sets (Spearman's rho ¼ 0.81, P , 0.0001), also evident after excluding samples with zero abundance (see Fig. S3 , Supplemental Digital Content 1, http://links.lww.com/IBD/B636). Importantly, the V4 subsample also validated other bacterial alterations in patients with FGDS compared with unrelated (P , 0.001) and related HC (P , 0.05) including Faecalibacterium, Bifidobacterium, and Enterobacteriaceae (Table 2 and 
Disease Outcome and Microbiota Associations in FGDS
The abundance of Faecalibacterium was markedly reduced in FGDS patients with CD (N ¼ 5) compared with those without CD (N ¼ 15, P ¼ 0.015, Fig. 4D ), with the latter still showing reduced abundance of Faecalibacterium compared with related HC (P ¼ 0.011, Fig. 4D ). These findings were confirmed with V4 data (P ¼ 0.005 and P ¼ 0.003). Of note, FGDS with CD had significantly lower abundance of Faecalibacterium even compared with conventional patients with CD (N ¼ 9, P ¼ 0.039). When looking at global microbiota composition measured by beta diversity, a significant separation in microbial composition was seen in the small subgroups of conventional CD (N ¼ 9) and FGDS with CD (N ¼ 5, P ¼ 0.02, unweighted UniFrac, Fig. S5 , Supplemental Digital Content 1, http://links.lww.com/IBD/B636). When exploring the effect of FGDS in CD in detail in this small number of patients, there were both a large number of overlapping (see Table S4 , Supplemental Digital Content 1, http://links.lww.com/IBD/B636) and nonoverlapping (see Table S5 , Supplemental Digital Content 1, http://links.lww.com/IBD/B636) taxa in FGDS with CD compared with conventional CD. When looking further at the effect of CD in FGDS, Fusobacterium was enriched in FGDS patients with CD compared with those without CD (P ¼ 0.034, see Table S6 , FIGURE 2. Alpha diversity, here illustrated by the Shannon diversity index was unchanged in FGDS compared with HC. By contrast, and similar to other studies, alpha diversity was reduced in unrelated patients with IBD. Boxes represent interquartile range (IQR), whiskers define highest and lowest data within 1.5 IQR from upper and lower boundary of IQR, respectively. **P , 0.005, ***P , 0.001. Because stool consistency is a strong determinant of the gut microbiota and could be affected by intestinal inflammation, we evaluated possible correlations between reported diarrhea, CD status, and key microbiota findings in patients with FGDS. Reported severity of diarrhea was associated with CD status (P ¼ 0.016), correlated with loss of alpha diversity (Shannon diversity index, Spearman's rho 20.53, P ¼ 0.017) and a loss of Methanobrevibacter (Spearman's rho 20.65 P ¼ 0.002, V4 data, see Table S4 , Supplemental Digital Content 1, http://links.lww.com/IBD/B636).
Dietary Habits in Patients with FGDS and Healthy Relatives
Eighteen patients with FGDS (90%) and 11 related HC (92%) completed food frequency questionnaires for assessment of diet. There was no significant difference in the intake of fat, protein, carbohydrates, fiber or added sugars, and alcohol between these groups (Table 3) . A reported EI/BMR ratio less than 1.12, which is consistent with underreporting, was found in 2 patients with FGDS (11%) and 1 healthy relative (9%). 35 
DISCUSSION
We present a cross-sectional study of the intestinal microbiota in patients with FGDS, a monogenic disorder caused by an activating mutation in GUCY2C, characterized by chronic mild secretory diarrhea and high prevalence of CD. 9 Regardless of CD status, patients with FGDS harbored a highly distinct intestinal microbiota with marked depletion of Faecalibacterium and Bifidobacterium and increases of Enterobacteriaceae, but no difference in alpha diversity, compared with HC. Assessments of healthy relatives and diet suggest that the alterations were not driven by environmental or other familial factors, and support that GC-C deregulation (by the GUCY2C mutation) shapes the intestinal microbiota, possibly with proinflammatory potential. These observations may be of general interest given the recent introduction of pharmaceuticals that directly target GC-C activity. 42, 43 To our knowledge, this is the first study on the impact of genetic variation of GUCY2C on the human intestinal microbiota, and there are thus little data available for comparison. Robust evidence from both twin cohorts and population studies now suggest that there are significant effects of heritable factors on the gut microbiota in humans. [44] [45] [46] [47] However, the individual effects from common variants in different genes are far smaller than the Whiskers define highest and lowest data within 1.5 IQR from higher and lower boundary of IQR, respectively. Outliers and extreme outliers are shown as circular spots with and without black boundary, respectively. ***P , 0.001, **P , 0.005, and *P , 0.05. extensive alterations observed in patients with familial diarrhea in this study, 44, 47 suggesting that the GUCY2C mutation has a major impact on intestinal ecology. The activating GUCY2C mutation in patients with FGDS could presumably alter the intraluminal environment and increase pH. 10 Interestingly, in controlled experiments, increasing pH was associated with increased growth of Enterobacteriaceae and reduced growth of Actinobacteria and Faecalibacterium, while maintaining alpha diversity. 48, 49 These observations are in line with the findings of this study, suggesting that altered pH could be 1 important factor influencing the microbiota. Adult patients with FGDS (as included in this study) have variable, but fairly mild, diarrheal disease with on average 3 to 4 loose stools per day. 9 In the general population, loose stools correlate with loss of alpha diversity and taxonomic changes such as loss of the genus Methanobrevibacter, possibly representing adaptations to fast intestinal transit associated with loose stools. 50 Loss of alpha diversity and depletion of Methanobrevibacter were indeed correlated with reported severity of diarrhea in FGDS. Still, on a group level, alpha diversity remained unchanged and Methanobrevibacter enriched in FGDS. Overall, this suggests the presence of mechanisms in these patients that counteract a "wash-out" effect of diarrhea.
Patients with FGDS have a strong predisposition to small bowel obstruction that could indicate intestinal dysmotility and slow transit. 9 In support of this, recent data from our group showed small intestinal fluid stagnation and increased nonpropulsive motility in these patients. 51 Interestingly, certain microbial strains may have an influence on intestinal motility, including a slowing effect of Methanobrevibacter (increased in FGDS) and a stimulating effect of Bifidobacterium (depleted in FGDS). 52, 53 Changes in these 2 genera were reported in patients with irritable bowel syndrome who display clinical similarities with FGDS, including intestinal dysmotility and changes in stool consistency. 54 It can be speculated that dysmotility in part is secondary to altered gut microbial profiles caused by GC-C activity, but such a causal link could only be determined in prospective evaluation, e.g., by explorative interventional studies with GC-C activating drugs. 54 The observed high prevalence of CD in patients with FGDS prompted the question as to whether an inflammatory intestinal environment contributes to the shifts observed in the microbiota. Endoscopy at enrollment would be the gold standard for assessing the presence of intestinal inflammation, but to secure maximal recruitment of participants we used clinical symptom scores and fecal calprotectin as less invasive indicators. Fecal calprotectin, a highly sensitive marker of intestinal inflammation, was normal in most of the patients with FGDS, and even in FGDS patients with CD, the median calprotectin was 10-fold lower than that in conventional CD. We cannot rule out that measurements of calprotectin in patients with diarrhea are liable to underestimate inflammation because of a diluting effect, but the generally low calprotectin levels in this group indicate an absence of gross inflammation. Alpha diversity is sensitive to inflammation and is consistently decreased in IBD. 3 This was also the case in the unrelated patients with IBD in our study, whereas alpha diversity was unchanged in patients with FGDS supporting that inflammation is a minor contributor to the microbial changes observed in these patients. Still, a tendency toward loss of alpha diversity was apparent in patients with FGDS diagnosed with CD, and similar to conventional patients with CD, this subgroup also displayed an enrichment of Fusobacterium and Pseudomonas and depletion of Firmicutes and F. prausnitzii. [55] [56] [57] When further looking at the effect of FGDS in patients with CD, FGDS patients with CD were significantly different from conventional CD as measured by beta diversity. In exploratory analyses, many additional taxa had different relative abundance in CD with and without FGDS, suggesting a significant effect of FGDS also in patients with CD. Still, many taxa also overlap, which together with the reported increased severity of diarrhea in FGDS patients with CD could be secondary to inflammation. However, loss of F. prausnitzii was accentuated also in FGDS patients without CD compared with HCs, supporting the notion that GC-C activation drives this CD-associated alteration. F. prausnitzii may modulate intestinal inflammation, e.g., by producing butyric acid, and loss of this species is both a hallmark and a prognostic marker of CD. 3, 55 Determining the initiating events in patients with CD is challenging given that the intestinal microbiota, its metabolites, intestinal hydration, and inflammation may display multidirectional relationships. 58 However, in line with other available data on the intestinal microbiota in humans at risk of IBD, our findings support that heritable factors induce a loss of F. prausnitzii and other IBD-associated microbiota changes preceding the development of intestinal inflammation. 4, 5, 59 An impact on host intestinal ion channels and inflammatory pathways, including a therapeutic effect in patients with diarrhea, has been reported for Bifidobacterium, a genus that exhibited an almost complete depletion in the patients with FGDS. 60, 61 Treatment with Bifidobacterium in probiotic formula in these patients remains to be systematically evaluated, but the striking lack of this genus suggests that high GC-C activity drives environmental conditions that inhibit the intestinal presence of Bifidobacterium. By contrast, patients with FGDS exhibited a marked enrichment of Enterobacteriaceae. This family of Gram-negative bacteria includes species shown to invade the intestinal mucosa of patients with CD. 62 It could thus be argued that GC-C activity causes distinct shifts in different bacterial groups, which could potentially explain the increased susceptibility to intestinal inflammation and CD in these patients.
Diet has an impact on the intestinal microbiota and could be altered because of chronic diarrhea. 7 This possible major confounder was therefore specifically addressed. The intake of a range of nutrients, as calculated by validated food frequency questionnaires, was similar in the patients with FGDS and the related controls. Conversely, the microbiota differed between family members with and without FGDS, whereas it was similar in related and unrelated HC, indicating that the GC-C activating mutation constitutes the major determining factor in shaping the microbiota in the patients with FGDS, and that diet and other family-associated environmental exposures play a lesser role.
Although an activating GUCY2C mutation clearly impacts the luminal microbiota, further studies are needed to establish the exact role of GC-C signaling in regulating the microbiota and whether this is relevant for disease outcome. This would be important to determine because associations between GC-C pathway alterations and IBD may include genetic risk variants common in the population as well as transcriptional and epigenetic changes observed in IBD intestinal mucosa. 1, [11] [12] [13] Also, current knowledge linking dietary habits, GC-C signaling changes, and colorectal cancer remain to address the intestinal microbiota. 16 GC-C blocking drugs are under development, and GC-C activating drugs are increasingly being used against abdominal pain and constipation in the common disorder irritable bowel syndrome and have been proposed as a treatment for UC and colorectal cancer. 16, 43 This study provides a strong motivation to evaluate the intestinal microbiota as a biomarker and a potential target of these drugs. 42, 43 Although causality cannot be determined with a crosssectional design, this study shows that FGDS patients with and without CD share microbial characteristics with conventional patients with IBD that are considered influential for the development of intestinal inflammation. Associations between disease outcome, symptoms, and microbiota within the FGDS group should be interpreted with caution because of a small sample size, but the between-group alterations are extensive and the results strengthened by repeated sampling, technical validation, and the use of both unrelated and familial controls as well as complementary statistical methods.
In summary, this study identifies a major shift in the fecal microbiota of patients with FGDS, probably related to the altered intestinal environment caused by the GC-C activating mutation. It can be speculated that these alterations could contribute to symptoms and predisposition to CD in these patients. Given the pharmacological importance of the GC-C pathway and unknown clinical implications of the altered gut environment, further studies of these associations are highly warranted.
